This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
March 29, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the release of two peer-reviewed publications related to SURFAXIN
® (lucinactant) Intratracheal Suspension. SURFAXIN, currently the only FDA approved synthetic alternative to animal-derived surfactants in the U.S., was highlighted in the December issue of the
Journal of Pediatric Pharmacology and Therapeutics (JPPT), in an article titled "
A Pharmacoeconomic Analysis of In-Hospital Costs Resulting from Reintubation in Preterm Infants Treated with Lucinactant, Beractant, or Poractant Alfa", as well as this month's issue of
Expert Reviews in Clinical Pharmacology in an article titled "
Lucinactant for the Prevention of Respiratory Distress Syndrome in Premature Infants".
"We believe the growing body of peer-reviewed scientific literature for SURFAXIN will better inform physicians and other decision makers considering formulary adoption of SURFAXIN," said Dr.
Russell G. Clayton, Senior Vice President, Research & Development, of Discovery Labs.
The publications are as follows:
A Pharmacoeconomic Analysis of In-Hospital Costs Resulting from Reintubation in Preterm Infants Treated with Lucinactant, Beractant, or Poractant Alfa – JPPT
September 2012, Vol. 17, No. 3, pp. 220-227
A pharmacoeconomic analysis previously presented at the 2012 Pediatric Academic Society Annual Conference and now published in the most recent issue of JPPT shows the lower rate of reintubation previously observed in infants treated with SURFAXIN, when compared with infants treated with the market leading surfactants, Curosurf
® and Survanta
®, resulted in a potential hospital cost savings associated with a reduction in need for mechanical ventilation.
Lucinactant for the Prevention of Respiratory Distress Syndrome in Premature Infants- Expert Rev. Clin. Pharmacol.
March 2013, Vol. 6, No. 2, Pages 115-121
In an independent review,
Expert Reviews authors provide a comprehensive assessment of lucinactant based on a compilation of available peer-reviewed publications that have discussed the safety, efficacy, and potential pharmacoeconomic impact of lucinactant in the prevention of respiratory distress syndrome (RDS). As the first synthetic, peptide-containing surfactant approved by the FDA, the authors indicate that SURFAXIN can be reproducibly manufactured and may reduce certain cultural or religious objections sometimes presented by parents with the use of animal-derived medications in their infants who are at risk for RDS. Furthermore, the authors discuss the future of surfactant replacement therapy, including potential aerosolization of lucinactant, which could allow for a less invasive approach to treating RDS.
IMPORTANT SAFETY INFORMATION SURFAXIN (lucinactant) Intratracheal Suspension is intended for intratracheal use only. The administration of exogenous surfactants, including SURFAXIN, can rapidly affect oxygenation and lung compliance. SURFAXIN should be administered only by clinicians trained and experienced with intubation, ventilator management, and general care of premature infants in a highly supervised clinical setting. Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.
Most common adverse reactions associated with the use of SURFAXIN are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption. During SURFAXIN administration, if bradycardia, oxygen desaturation, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted and the infant's clinical condition assessed and stabilized. SURFAXIN is not indicated for use in acute respiratory distress syndrome (ARDS).